WCN26-3497 HEALTH EFFECTS OF FERRIC CARBOXYMALTOSE SUPPLEMENTATION IN IRON-DEFICIENT KIDNEY TRANSPLANT RECIPIENTS: RESULTS OF A RANDOMIZED CONTROLLED TRIAL

Read full text Summarise with VIRAT
Authors: Joanna Sophia J. Vinke, Michele Freerk Eisenga, Amarens van der Vaart, Caspar van Lieshout, Helma Dolmans, Peter van der Meer, Jozine M. ter Maaten, Jacoba Spikman, Lisa Ziengs, Ilja Maria Nolte, Stefan P. Berger, Jan-Stephan F. Sanders
+3 more Stephan J. L. Bakker, Arjan D. van Zuilen, Martin H. de Borst
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Iron deficiency (ID) affects ±30% of kidney transplant recipients (KTR). In previous observational studies in KTR, ID was independently associated with poor quality of life and cognitive functioning and a higher risk of all-cause and cardiovascular mortality. In chronic heart failure, ID correction improves exercise capacity, cardiac function and quality of life; whether these effects also occur in KTR is unknown. The main objective of this trial was to address whether intravenous ferric carboxymaltose (FCM) improves exercise capacity in iron-deficient KTR.

Fields of Study & Subjects

Iron Metabolism and Disorders Erythropoietin and Anemia Treatment Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106397–106397
Publication date
25 March 2026
Language
EN